Rebecca (Becky) Taylor is a senior level executive with solid background in visualizing and guiding new ventures including building committed teams and raising funds. Deep commitment to the power of personal and organizational networking. Experience in organizations ranging in size from very small start-up companies to multinationals and senior advisory roles at the U.S. Department of State. Skilled at analysis and distilling complex facts down to small set of relevant parameters. Other expertise includes technology licensing, venture capital investing, sales negotiations, identifying market opportunities. Multiple patent holder. Advisor to startups on funding strategies, technology planning, and negotiations. Prefer presenting to diverse audiences, large and small. Lifelong commitment of raising money and awareness for important community needs. One of the first EIRs at UT in 2009, graduated LBJ School as a non-traditional student in 2010.
Ms. Taylor’s most recent role involved leading a healthcare technology startup as Chief Operating Officer, through first revenue, funding round close and executive team expansion. At SensorRX, she was responsible for a broad range of actions pertaining to business operations and strategy. SensorRX is a chronic disease management technology provider initially focused on migraine headache management. Previously, Ms. Taylor held roles as Technology Innovation Advisor at Royal Dutch Shell, where she looked externally to find new technologies that improve operations in the global Wells, Deepwater, Water technology development groups at Shell, and as a Venture Principal with Shell Technology Ventures (STV), the corporate venture capital arm of Shell. Prior to joining STV, Ms. Taylor served as IEEE Diplomacy Fellow and Senior Advisor at the U.S. State Department, where she connected various bureaus and offices with the U.S. startup and university commercialization communities.
SensorRX is a chronic disease management technology provider. It partners with large healthcare systems to improve treatment effectiveness and reduce the costs associated with a variety of chronic disease pathologies. The first chronic disease chosen to address, severe headache/migraine, counts 40 million US citizens amongst its sufferers. The company has reached the next stage in its growth and has relocated to Charlotte, NC. Becky served at the COO since 2016 and is now a shareholder, investor and as-needed advisor.